Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).
Cheung CC, Barnes P, Bigras G, Boerner S, Butany J, Calabrese F, Couture C, Deschenes J, El-Zimaity H, Fischer G, Fiset PO, Garratt J, Geldenhuys L, Gilks CB, Ilie M, Ionescu D, Lim HJ, Manning L, Mansoor A, Riddell R, Ross C, Roy-Chowdhuri S, Spatz A, Swanson PE, Tron VA, Tsao MS, Wang H, Xu Z, Torlakovic EE; Canadian Association of Pathologists-Association Canadienne Des Pathologistes’ National Standards Committee for High Complexity Testing (CAP-ACP NSCHCT).
Cheung CC, et al. Among authors: riddell r.
Appl Immunohistochem Mol Morphol. 2019 Nov/Dec;27(10):699-714. doi: 10.1097/PAI.0000000000000800.
Appl Immunohistochem Mol Morphol. 2019.
PMID: 31584451
Free PMC article.